Ascentage Pharma Group International (AAPG) Non-Current Deffered Revenue: 2023-2024
- Ascentage Pharma Group International's Non-Current Deffered Revenue fell 2.43% to $34.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $34.0 million, marking a year-over-year decrease of 2.43%. This contributed to the annual value of $34.0 million for FY2024, which is 4.23% down from last year.
- Latest data reveals that Ascentage Pharma Group International reported Non-Current Deffered Revenue of $34.0 million as of Q4 2024, which was down 2.43% from $34.9 million recorded in Q4 2023.
- In the past 5 years, Ascentage Pharma Group International's Non-Current Deffered Revenue registered a high of $34.9 million during Q4 2023, and its lowest value of $34.0 million during Q4 2024.
- For the 2-year period, Ascentage Pharma Group International's Non-Current Deffered Revenue averaged around $34.5 million, with its median value being $34.5 million (2023).
- Data for Ascentage Pharma Group International's Non-Current Deffered Revenue shows a maximum YoY fell of 2.43% (in 2024) over the last 5 years.
- Ascentage Pharma Group International's Non-Current Deffered Revenue (Quarterly) stood at $34.9 million in 2023, then dropped by 2.43% to $34.0 million in 2024.
